HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by D'Alessio, D. A. Articles by Vahl, T. P. Search for Related Content PubMed PubMed Citation Articles by D'Alessio, D. A. Articles by Vahl, T. P.

MINIREVIEW

Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes

Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267

Glucagon-like peptide 1 (GLP-1) is a product of proglucagon that is secreted by specialized intestinal endocrine cells after meals. GLP-1 is insulinotropic and plays a role in the incretin effect, the augmented insulin response observed when glucose is absorbed through the gut. GLP-1 also appears to regulate a number of processes that reduce fluctuations in blood glucose, such as gastric emptying, glucagon secretion, food intake, and possibly glucose production and glucose uptake. These effects, in addition to the stimulation of insulin secretion, suggest a broad role for GLP-1 as a mediator of postprandial glucose homeostasis. Consistent with this role, the most prominent effect of experimental blockade of GLP-1 signaling is an increase in blood glucose. Recent data also suggest that GLP-1 is involved in the regulation of -cell mass. Whereas other insulinotropic gastrointestinal hormones are relatively ineffective in stimulating insulin secretion in persons with type 2 diabetes, GLP-1 retains this action and is very effective in lowering blood glucose levels in these patients. There are currently a number of products in development that utilize the GLP-1-signaling system as a mechanism for the treatment of diabetes. These compounds, GLP-1 receptor agonists and agents that retard the metabolism of native GLP-1, have shown promising results in clinical trials. The application of GLP-1 to clinical use fulfills a long-standing interest in adapting endogenous insulinotropic hormones to the treatment of diabetes.

glucose tolerance; insulin secretion

This article has been cited by other articles:

				D. D'Alessio Intestinal Hormones and Regulation of Satiety: The Case for CCK, GLP-1, PYY, and Apo A-IV JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 567 - 568. [Abstract] [Full Text] [PDF]

				D. E. Cummings Gastric Bypass and Nesidioblastosis -- Too Much of a Good Thing for Islets? N. Engl. J. Med., July 21, 2005; 353(3): 300 - 302. [Full Text] [PDF]

				X. Qin, H. Shen, M. Liu, Q. Yang, S. Zheng, M. Sabo, D. A. D'Alessio, and P. Tso GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G943 - G949. [Abstract] [Full Text] [PDF]